Provided by Tiger Trade Technology Pte. Ltd.

Aktis Oncology

18.38
-0.1400-0.76%
Volume:153.44K
Turnover:2.80M
Market Cap:1.02B
PE:-13.44
High:18.82
Open:18.75
Low:17.93
Close:18.52
52wk High:34.19
52wk Low:14.72
Shares:55.28M
Float Shares:17.65M
Volume Ratio:0.98
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3680
EPS(LYR):-78.3394
ROE:-29.45%
ROA:-15.79%
PB:2.10
PE(LYR):-0.23

Loading ...

Aktis Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 03

Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright

TIPRANKS
·
Jun 03

Aktis Oncology, Inc. : H.c. Wainwright Raises Target Price to $35 From $33

THOMSON REUTERS
·
Jun 02

Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update

TIPRANKS
·
May 28

Aktis Oncology CEO to present at Jefferies Global Healthcare Conference

Reuters
·
May 28

Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity

TIPRANKS
·
May 27

Aktis Oncology posts presentation on AKY-2519 clinical imaging, dosimetry data for B7-H3-targeted radioconjugate

Reuters
·
May 27

Top Premarket Gainers

MT Newswires Live
·
May 22

Aktis Oncology (AKTS) Valuation Check After Recent Share Price Weakness And Lower Price To Book Ratio

Simply Wall St.
·
May 22

Aktis Oncology reports first-in-human AKY-2519 imaging data showing robust tumor uptake

Reuters
·
May 22

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for Aky-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients With B7-H3 Expressing Tumors

THOMSON REUTERS
·
May 22

Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Metagenomi, Inc. (MGX)

TIPRANKS
·
May 12

Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M

TIPRANKS
·
May 12

Aktis Oncology Q1 EPS $(0.38) Beats $(0.44) Estimate, Sales $3.227M Beat $1.750M Estimate

Benzinga Earnings
·
May 12

Aktis Oncology Q1 FY26 net loss widens to $18.3 million; revenue climbs to $3.2 million

Reuters
·
May 12

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

GlobeNewswire
·
May 12

Aktis Oncology to Present at the BofA Securities Health Care Conference

GlobeNewswire
·
May 06

Aktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and mCRPC Opportunity for AKY‑2519

TIPRANKS
·
May 05

Aktis Oncology posts presentation outlining AKY-2519 Phase 1b clinical development strategy

Reuters
·
May 05

Aktis Oncology initiates clinical trial of AKY-25191

TIPRANKS
·
May 05